Get the Stockscreener App
7.33
3.81%
-0.29
Pre-market:
7.27
-0.06
-0.82%
Nuvectis Pharma Inc stock is traded at $7.33, with a volume of 86,614.
It is down -3.81% in the last 24 hours and up +16.53% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$7.62
Open:
$7.62
24h Volume:
86,614
Relative Volume:
0.82
Market Cap:
$171.46M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-5.1986
EPS:
-1.41
Net Cash Flow:
$-15.54M
1W Performance:
+15.62%
1M Performance:
+16.53%
6M Performance:
+13.82%
1Y Performance:
-27.78%
1-Day Range:
$7.01
$7.8999
1-Week Range:
$6.00
$7.99
52-Week Range:
$4.44
$12.10
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
7.33 | 171.46M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
Oppenheimer & Co. Inc. Takes Position in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
(NVCT) Proactive Strategies - Stock Traders Daily
Nuvectis announces new publication of research study on NXP900, osimertinib - TipRanks
Nuvectis reports promising cancer treatment results - Investing.com
Nuvectis Pharma Announces a New Publication of a Research - GlobeNewswire
Cleveland Clinic Study Confirms: Nuvectis Drug Makes Standard Lung Cancer Treatment More Effective - StockTitan
Q1 EPS Estimates for Nuvectis Pharma Reduced by Roth Capital - Defense World
HC Wainwright Weighs in on Nuvectis Pharma Q1 Earnings - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Nuvectis Pharma (NVCT) to Release Earnings on Tuesday - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Price Target Lowered to $11.00 at HC Wainwright - MarketBeat
FY2028 EPS Forecast for Nuvectis Pharma Reduced by Analyst - MarketBeat
FY2028 EPS Estimates for Nuvectis Pharma Reduced by Analyst - Defense World
Nuvectis Pharma Reports 2024 Financial Results and Progress - TipRanks
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets - Marketscreener.com
HC Wainwright Lowers Nuvectis Pharma (NASDAQ:NVCT) Price Target to $11.00 - Defense World
Nuvectis Pharma Reports 2024 Financial Results and Updates on Oncology Pipeline - Defense World
Nuvectis Pharma initiated with a Buy at Lucid Capital - TipRanks
Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position - TipRanks
Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright - TipRanks
Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year - TipRanks
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights - The Manila Times
How Nuvectis Pharma Cut Losses by $3.3M While Pushing Forward Two Cancer Drug Candidates - StockTitan
Insiders Rewarded With US$915k Addition To Investment As Nuvectis Pharma Stock Hits US$185m - Simply Wall St
Nuvectis Pharma announces pricing of $13.5M public offering - MSN
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Purchases $1,200,000.00 in Stock - MarketBeat
Nuvectis pharma investor acquires $1.2 million in stock - MSN
(NVCT) Investment Analysis and Advice - Stock Traders Daily
Nuvectis Pharma Insider Bought Shares Worth $1,200,000, According to a Recent SEC Filing - Marketscreener.com
Major Investment Alert: Shareholder’s Big Move in Nuvectis Pharma! - TipRanks
Nuvectis pharma investor acquires $1.2 million in stock By Investing.com - Investing.com
Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering - MSN
Nuvectis Pharma Closes Stock Offering, Says Underwriter Exercised Overallotment Option - Marketscreener.com
Nuvectis Pharma Announces Closing of $15.5 Million Public - GlobeNewswire
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option - Yahoo Finance
Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback - Seeking Alpha
Nuvectis Pharma launches public stock offering - MSN
Nuvectis Pharma 2.7M share Spot Secondary priced at $5.00 - MSN
Nuvectis Pharma Prices $13.5 Million Public Offering of Shares -February 05, 2025 at 10:52 am EST - Marketscreener.com
Nuvectis Pharma Prices of $13.5 Million Public Offering of Common Stock - citybiz
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock - GlobeNewswire
Nuvectis pharma announces proposed public offering of common stock - MSN
Nuvectis Secures Critical $13.5M Funding: Major Push for Revolutionary Cancer Drug Development - StockTitan
Nuvectis Pharma launches public stock offering By Investing.com - Investing.com Australia
Nuvectis Pharma Announces Proposed Public Offering of Common Stock - GlobeNewswire
Nuvectis Pharma's Strategic Funding Move: Key Details on Oncology Pipeline Investment - StockTitan
(NVCT) Trading Signals - Stock Traders Daily
Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
2.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):